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Access to flucytosine for HIV-infected 
patients with cryptococcal meningitis 
– an urgent need
To the Editor: The addition of oral flucytosine to an amphotericin 
B-containing induction regimen for HIV-associated cryptococcal 
meningitis (CM) is associated with improved fungal clearance and 
a 39% reduction in 10-week mortality.[1] Owing to the unacceptably 
high mortality associated with CM, access to flucytosine needs to be 
prioritised in South Africa (SA), together with interventions such 
as earlier detection of cryptococcal disease.[2] The World Health 
Organization (WHO) recommended amphotericin B and flucytosine 
as the preferred induction regimen in rapid advice guidelines, 
and in 2013 included these agents in the WHO Model Lists of 
Essential Medicines as part of the ‘core list’.[3,4] In line with WHO 
recommendations, the Southern African HIV Clinicians Society 
has strongly supported efforts to obtain access to flucytosine in 
updated clinical guidelines.[5] In 2012, amphotericin B was prescribed 
for more than 80% of patients with CM at predominantly urban 
sentinel hospitals.[6] The addition of flucytosine would not add much 
complexity to this regimen. In a resource-limited setting, Day et al.[1] 
showed that it was feasible to use flucytosine instead of amphotericin 
B monotherapy with no additional toxicity and with the same panel 
of monitoring blood tests, i.e. full blood count and urea, electrolytes 
and creatinine. 
Even though flucytosine is a simple, off-patent agent that has 
been in clinical use for over five decades,[7] there are two major 
barriers to access in SA. First, while flucytosine is still registered 
with the Medicines Control Council (MCC), this registration has 
not been maintained. As a distributor for the innovator company, 
Roche first registered flucytosine with the MCC in the 1990s, but 
with drew the product from the market in the early 2000s. Currently, 
flucyto sine is only available for compassionate use through an MCC 
application (section 21 of the Medicines and Related Substances 
Control Act 1965), a process that may take several weeks. Second, US 
Food and Drug Administration (FDA)-approved flucytosine obtained 
through the innovator company, Meda Pharmaceuticals/Valeant, 
or a US-based generic manufacturer, Sigmapharm Laboratories, is 
expensive.[8] Based on an approximate price of R13.00 per 500 mg 
tablet, a 14-day treatment course for a 50 kg adult at a dose of 
100 mg/kg/d would cost R1 820.00.[8] Since amphotericin B currently 
costs approximately R700.00 for 14 days, adding R1 820.00 inflates 
the drug cost of induction-phase treatment by >300%.[9] Loyse et al.[10] 
have suggested that high costs have persisted as a result of a market 
failure. However, demand for flucytosine can be reinvigorated: 
surveillance case numbers can be used for drug forecasting by 
manufacturers (approximately 7 000 cases were diagnosed in 2012[6]), 
best clinical practice guidelines have been developed,[5] and pooled 
procurement of flucytosine with other anti-infective agents may 
increase bargaining power.
While few manufacturers have expressed interest in production 
of low-cost generic flucytosine, local distributors have expressed 
willingness to negotiate with manufacturers of FDA-approved 
flucytosine and apply for fast-track updated registration of the drug. 
If these efforts are successful, we motivate that flucytosine should be 
included in the SA Essential Medicines List for hospitals, along with 
amphotericin B. 
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